CORONA REMEDIES
Back to Cashflow Statement
|
CORONA REMEDIES Last 5 Year Net Cash Inflow / Outflow History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | |
|---|---|---|---|---|
| Net Cash Inflow / Outflow | ₹-1.39 Cr | ₹0.06 Cr | ₹-11 Cr | ₹7.71 Cr |
What is the latest Net Cash Inflow / Outflow ratio of CORONA REMEDIES ?
| Year | Net Cash Inflow / Outflow |
|---|---|
| Mar2026 | ₹-1.39 Cr |
| Mar2025 | ₹0.06 Cr |
| Mar2024 | ₹-11 Cr |
| Mar2023 | ₹7.71 Cr |
How is Net Cash Inflow / Outflow of CORONA REMEDIES Trending?
| Years | Net Cash Inflow / Outflow | % Change | |
|---|---|---|---|
| Mar2026 | ₹-1.39 Cr | Negative | |
| Mar2025 | ₹0.06 Cr | Positive | |
| Mar2024 | ₹-11 Cr | Negative | |
| Mar2023 | ₹7.71 Cr | - | |
Compare Net Cash Inflow / Outflow of peers of CORONA REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CORONA REMEDIES | ₹12,461.2 Cr | 3.4% | 20% | NA | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹456,989.0 Cr | 1.7% | 6.4% | 12.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹179,471.0 Cr | 3% | 2.8% | 0.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹161,290.0 Cr | 2.3% | 9.1% | 44.6% | Stock Analytics | |
| CIPLA | ₹117,820.0 Cr | 0.3% | 6.1% | -3.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹114,730.0 Cr | -0.1% | 8.9% | 1.9% | Stock Analytics | |
CORONA REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CORONA REMEDIES | 3.4% |
20% |
|
| SENSEX | 0.9% |
4.2% |
-6% |
You may also like the below Video Courses